drugs
New Cost Cap Steering Committee is industry-driven
The first meeting of the new Steering Committee to guide the Office of Health Strategy’s (OHS) plan to cap healthcare cost growth was uncharacteristically quiet. The meeting started with public comment from the Universal Healthcare Foundation of CT that the committee membership is “not balanced”, includes mainly members with “deep vested business interests”, and lacks…
Read MoreCT ranks 15th among states in healthcare affordability, but that’s not saying much
Connecticut has implemented many policies to make healthcare affordable; unfortunately, they aren’t working. According to Altarum’s new Healthcare Affordability State Policy Scorecard, Connecticut earned 43.1 out of 80 possible points. There is a lot of room for improvement. Altarum ranked states on adoption of policies that can impact affordability and on outcomes, whether care is…
Read MoreConnecticut hospital systems vary in reducing low-value care
A new report published in JAMA Internal Medicine on low-value care provided to Medicare beneficiaries at the health system level offers actionable tools to improve effective care on the ground. Healthcare services that provide little or no health benefit, may harm patients, increase costs, and waste resources are low-value. Examples include prostate specific antigen testing…
Read MoreCTNJ: OP-ED | Legislators Hear How RI Saved 2 Hospitals From Private Equity, Other Solutions to High Insurance Premiums
On Friday, in a forum sponsored by state Rep. Kerry Wood, six national and local experts gave legislators specific policy tools to help with health care market consolidation and rising drug prices that are driving up health insurance premiums. Legislators also got specific tools used by Rhode Island to avoid private equity abuses experienced in…
Read MoreCT residents over twice as likely to die of opioid or other drug poisoning than from alcohol
Connecticut ranked 17th lowest among states in alcohol-related deaths per capita, but seventh highest in opioid-related deaths in 2019, based on an analysis of data from SHADAC’s State Health Access Data Assistance Center. That year, Connecticut residents were 245% more likely to die from an opioid or other drug poisoning than from alcohol. (Opioid or…
Read MoreLegislative forum on drivers of rising health costs
Connecticut legislators will hear from experts on the drivers of rising health insurance premiums and options to control costs next Friday, September 24th at noon. The forum — Consolidation, Private Equity, and Drug Prices in Health Care Costs — is sponsored by Rep. Kerry Wood, Co-Chair of the Insurance and Real Estate Committee. The forum…
Read MoreCTNJ OP-ED | Congress Wants to Lower Drug Prices to Fund Important Priorities
Economists argue that rising healthcare costs crowd out resources for other societal priorities such as education, infrastructure, climate change, and housing. It makes sense in theory but, until lately, it seemed a bit abstract. But right now, Congress and the administration are making the point in very real terms. Policymakers want to make big investments…
Read MoreCTNJ: Insulin – Once a Gift, Now Serving Greed
Today is the hundredth anniversary of the discovery of insulin. Diabetes affects about 367,000 adults in Connecticut and that number is rising. Before the 1920s, a diabetes diagnosis was a death sentence. The discovery of insulin allowed people with diabetes to live their lives. Until the 1970s insulin was affordable, but it’s now so costly…
Read MoreCTNJ: CT needs to focus on real health reform
Connecticut insurance premiums were the sixth highest among states for both individual and family coverage in 2019. Making healthcare more affordable was the drumbeat from voters last year. But CT policymakers have responded with weak options that kick the can down the road. Controlling the drivers of health costs is advanced placement politics. Powerful industries…
Read MoreOP-ED | Controversial New Alzheimer’s Drug Could Break the Bank
Alzheimer’s disease affects six million Americans, stealing memories years before it takes lives. Aduhelm, the first drug intended to treat the Alzheimer’s disease process rather than symptoms, was highly anticipated by patients and families. But it has disappointed on many levels. It isn’t clear that it actually helps patients and troubling side effects are common.…
Read More